Takeover Rumors Surround Endo Health Solutions Inc (ENDP)

Endo Health Solutions Inc (NASDAQ:ENDP) shares popped more than 17% last week on rumors of exploratory talks with potential buyers including Valeant Pharmaceuticals Intl Inc (NYSE:VRX) and Warner Chilcott Plc (NASDAQ:WCRX). This week, Bloomberg reported that the push to sell might come from Fidelity Investments — Endo’s largest shareholder.

It’s best to take sale rumors with a bag of salt. But here’s a look back at the tough year that left Endo in a more vulnerable position.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)String of bad news
Branded pharmaceuticals made up the majority of Endo’s revenues last year. In the third quarter, the pain patch Lidoderm accounted for 32% of overall revenues and over half of its segment. The bad news? Lidoderm’s patent expired last fall. An expensive patent battle with Actavis Inc (NYSE:ACT), formerly Watson, delayed the generic release but only until this September .

Opana ER earned the second slot in the branded drug department, accounting for 8% of overall revenues that quarter following a 36% slip due to a supply issue. Endo replaced the original formula with a crush-resistant formulation that’s harder to abuse. The company later sued the FDA  to try and prevent generic alternatives from entering the market, claiming that their non-tamper-resistant nature posed a safety risk to patients. But a court dismissed the case and opened the path for generics.

In December, Endo announced that CEO David P. Holveck plans to step down this spring, and a search for a replacement is still under way. The company used the same press release to lower its 2013 forecast to include EPS of $4.40 to $4.70 per share and revenues of $2.80 billion to $2.95 billion. That’s down from the month-prior prediction with an EPS of $5.20 to $5.40 per share and revenues of $3 to $3.02 billion.

Bright spot
Endo has more happening than Lidoderm and Opana ER. The generic drug subsidiary Qualitest held 22% of overall revenues in the third quarter and future growth here could offset a bit of the losses from pharmaceuticals. Qualitest launched a generic for Merck & Co., Inc. (NYSE:MRK)‘s asthma medication Singulair last summer and later received FDA approvals for generic versions of Avapro and Provigil. The generics market tends to be competitive with low margins.

The article Takeover Rumors Surround This Drug Stock originally appeared on Fool.com and is written by Brandy Betz.

Fool contributor Brandy Betz has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top 6 Tax Scams and How to Protect Yourself

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!